Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

LESSONS LEARNED: Combination therapies in patients with hepatocellular carcinoma can be associated with overlapping toxicity and are therefore poorly tolerated. Using sorafenib at the maximum tolerated dose can lead to a higher incidence of toxicities. Consequently, combination studies might evaluat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Shahda, Safi, Loehrer, Patrick J., Clark, Romnee S., Spittler, A. John, Althouse, Sandra K., Chiorean, E. Gabriella
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2016
Konular:
Clinical Trial Results
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4912375/
https://ncbi.nlm.nih.gov/pubmed/27256874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0071
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller